Recent advances in p53 research and cancer treatment

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Suzuki, Kazufumi ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; ENZYME ACTIVITY; ESOPHAGUS CANCER; FAMILIAL CANCER; GENE MUTATION; GENE REGULATORY NETWORK; HELPER CELL; HUMAN; IMMUNE RESPONSE; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; STOMACH CANCER; TUMOR PROMOTION; CELL CYCLE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; IMMUNOTHERAPY; METABOLISM; MUTATION; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, P53; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052664208     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/978312     Document Type: Review

References (72)

1. Soussi T., Béroud C., Assessing TP53 status in human tumours to evaluate clinical outcome Nature Reviews Cancer 2001 1 3 233 240 (Pubitemid 33741898)
2. Vousden K. H., Prives C., Blinded by the light: the growing complexity of p53 Cell 2009 137 3 413 431
3. Riley T., Sontag E., Chen P., Levine A., Transcriptional control of human p53-regulated genes Nature Reviews Molecular Cell Biology 2008 9 5 402 412 (Pubitemid 351574202)
4. Petitjean A., Achatz M. I. W., Borresen-Dale A. L., Hainaut P., Olivier M., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 2007 26 15 2157 2165 (Pubitemid 46536647)
5. Brosh R., Rotter V., When mutants gain new powers: news from the mutant p53 field Nature Reviews Cancer 2009 9 10 701 713
6. Malkin D., Li F. P., Strong L. C., Fraumeni J. F., Nelson C. E., Kim D. H., Kassel J., Gryka M. A., Bischoff F. Z., Tainsky M. A., Friend S. H., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 1990 250 4985 1233 1238 (Pubitemid 120031831)
7. Wolf D., Harris N., Rotter V., Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene Cell 1984 38 1 119 126 (Pubitemid 15216541)
8. Oren M., Rotter V., Mutant p53 gain-of-function in cancer Cold Spring Harbor Perspectives in Biology 2010 2 2
9. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
10. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M., Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 Nature 1991 352 6333 345 347 (Pubitemid 21912356)
11. Toledo F., Krummel K. A., Lee C. J., Liu C. W., Rodewald L. W., Tang M., Wahl G. M., A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network Cancer Cell 2006 9 4 273 285
12. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C., Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 1994 9 6 1799 1805 (Pubitemid 24163411)
13. Miyashita T., Reed J. C., Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 1995 80 2 293 299
14. Oltvai Z. N., Milliman C. L., Korsmeyer S. J., Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death Cell 1993 74 4 609 619 (Pubitemid 23259742)
15. Cotter T. G., Apoptosis and cancer: the genesis of a research field Nature Reviews Cancer 2009 9 7 501 507
16. Yip K. W., Reed J. C., Bcl-2 family proteins and cancer Oncogene 2008 27 50 6398 6406
17. Ayhan A., Yasui W., Yokozaki H., Seto M., Ueda R., Tahara E., Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas Japanese Journal of Cancer Research 1994 85 6 584 591 (Pubitemid 24191233)
18. Hague A., Moorghen M., Hicks D., Chapman M., Paraskeva C., BCL-2 expression in human colorectal adenomas and carcinomas Oncogene 1994 9 11 3367 3370 (Pubitemid 24338467)
19. Krajewska M., Moss S. F., Krajewski S., Song KI., Holt P. R., Reed J. C., Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas Cancer Research 1996 56 10 2422 2427 (Pubitemid 26154093)
20. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius-V. M., Niskanen E., Nordling S., Reed J. C., Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Research 1995 55 19 4471 4478
21. Sjstrm J., Blomqvist C., Von Boguslawski K., Bengtsson N. O., Mjaaland I., Malmstrm P., Ostenstadt B., Wist E., Valvere V., Takayama S., Reed J. C., Saksela E., The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer Clinical Cancer Research 2002 8 3 811 816 (Pubitemid 34742112)
22. Trauth B. C., Klas C., Peters A. M., Matzku S., Moller P., Falk W., Debatin K. M., Krammer P. H., Monoclonal antibody-mediated tumor regression by induction of apoptosis Science 1989 245 4915 301 305 (Pubitemid 19196649)
23. Muller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J., Stremmel W., Krammer P. H., Galle P. R., Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 The Journal of Clinical Investigation 1997 99 3 403 413 (Pubitemid 27414797)
24. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M., Krammer P. H., P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs Journal of Experimental Medicine 1998 188 11 2033 2045 (Pubitemid 28562520)
25. Chen L., Park S. M., Tumanov A. V., Hau A., Sawada K., Feig C., Turner J. R., Fu Y. X., Romero I. L., Lengyel E., Peter M. E., CD95 promotes tumour growth Nature 2010 465 7297 492 496
26. Nakano K., Vousden K. H., PUMA, a novel proapoptotic gene, is induced by p53 Molecular Cell 2001 7 3 683 694 (Pubitemid 32706359)
27. Yu J., Zhang L., Hwang P. M., Kinzler K. W., Vogelstein B., PUMA induces the rapid apoptosis of colorectal cancer cells Molecular Cell 2001 7 3 673 682 (Pubitemid 32706358)
28. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N., Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 2000 288 5468 1053 1058 (Pubitemid 30324238)
29. Jeffers J. R., Parganas E., Lee Y., Yang C., Wang J., Brennan J., MacLean K. H., Han J., Chittenden T., Ihle J. N., McKinnon P. J., Cleveland J. L., Zambetti G. P., Puma is an essential mediator of p53-dependent and -independent apoptotic pathways Cancer Cell 2003 4 4 321 328 (Pubitemid 37329796)
30. Yu J., Zhang L., No PUMA, no death: implications for p53-dependent apoptosis Cancer Cell 2003 4 4 248 249 (Pubitemid 37329788)
31. Labi V., Erlacher M., Krumschnabel G., Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation Genes Development 2010 24 15 1602 1607
32. Michalak E. M., Vandenberg C. J., Delbridge A. R., Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death Genes Development 2010 24 15 1608 1613
33. Giono L. E., Manfredi J. J., The p53 tumor suppressor participates in multiple cell cycle checkpoints Journal of Cellular Physiology 2006 209 1 13 20 (Pubitemid 44318664)
34. Taylor W. R., Stark G. R., Regulation of the G2/M transition by p53 Oncogene 2001 20 15 1803 1815 (Pubitemid 32458690)
35. Campisi J., Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors Cell 2005 120 4 513 522 (Pubitemid 40269765)
36. Campisi J., d'Adda di Fagagna F., Cellular senescence: when bad things happen to good cells Nature Reviews Molecular Cell Biology 2007 8 9 729 740 (Pubitemid 47312822)
37. Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W., Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 1997 88 5 593 602 (Pubitemid 27152402)
38. Xue W., Zender L., Miething C., Dickins R. A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S. W., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 2007 445 7128 656 660 (Pubitemid 46232886)
39. Bertheau P., Espié M., Turpin E., Lehmann J., Plassa L. F., Varna M., Janin A., De Thé H., TP53 status and response to chemotherapy in breast cancer Pathobiology 2008 75 2 132 139 (Pubitemid 351820731)
40. Martins C. P., Brown-Swigart L., Evan G. I., Modeling the therapeutic efficacy of p53 restoration in tumors Cell 2006 127 7 1323 1334 (Pubitemid 44960417)
41. Ventura A., Kirsch D. G., McLaughlin M. E., Tuveson D. A., Grimm J., Lintault L., Newman J., Reczek E. E., Weissleder R., Jacks T., Restoration of p53 function leads to tumour regression in vivo Nature 2007 445 7128 661 665 (Pubitemid 46232887)
42. Boeckler F. M., Joerger A. C., Jaggi G., Rutherford T. J., Veprintsev D. B., Fersht A. R., Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10360 10365
43. Bykov V. J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K. G., Selivanova G., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nature Medicine 2002 8 3 282 288 (Pubitemid 34250107)
44. Rippin T. M., Bykov V. J., Freund S. M. V., Selivanova G., Wiman K. G., Fersht A. R., Characterization of the p53-rescue drug CP-31398 in vitro and in living cells Oncogene 2002 21 14 2119 2129 (Pubitemid 34311366)
45. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B., Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 1992 358 6381 80 83
46. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P., Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations Cancer Research 1993 53 12 2736 2739 (Pubitemid 23180507)
47. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004 303 5659 844 848 (Pubitemid 38174664)
48. Shangary S., Qin D., McEachern D., Liu M., Miller R. S., Qiu SU., Nikolovska-Coleska Z., Ding KE., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R. B., Pienta K. J., Ling X., Kang S., Guo M., Sun YI., Yang D., Wang S., Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proceedings of the National Academy of Sciences of the United States of America 2008 105 10 3933 3938 (Pubitemid 351723502)
49. Ringshausen I., O'Shea C. C., Finch A. J., Swigart L. B., Evan G. I., Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo Cancer Cell 2006 10 6 501 514 (Pubitemid 44854749)
50. Lain S., Hollick J. J., Campbell J., Staples O. D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K. E., Baker L., Thompson A., Mathers J., Holland S. J., Stark M. J. R., Pass G., Woods J., Lane D. P., Westwood N. J., Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008 13 5 454 463 (Pubitemid 351609441)
51. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L. G. G. C., Masucci M., Pramanik A., Selivanova G., Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nature Medicine 2004 10 12 1321 1328 (Pubitemid 40022713)
52. Enge M., Bao W., Hedstrm E., Jackson S. P., Moumen A., Selivanova G., MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53 Cancer Cell 2009 15 3 171 183
53. Komarov P. G., Komarova E. A., Kondratov R. V., Christov-Tselkov K., Coon J. S., Chernov M. V., Gudkov A. V., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 1999 285 5434 1733 1737 (Pubitemid 29428873)
54. Roth J. A., Nguyen D., Lawrence D. D., Kemp B. L., Carrasco C. H., Ferson D. Z., Hong W. K., Komaki R., Lee J. J., Nesbitt J. C., Pisters K. M. W., Putnam J. B., Schea R., Shin D. M., Walsh G. L., Dolormente M. M., Han C. I., Martin F. D., Yen N., Xu K., Stephens L. C., Mcdonnell T. J., Mukhopadhyay T., Cai D., Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer Nature Medicine 1996 2 9 985 991 (Pubitemid 26306836)
55. Zhang W. W., Fang X., Mazur W., French B. A., Georges R. N., Roth J. A., High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus Cancer Gene Therapy 1994 1 1 5 13
56. Shimada H., Matsubara H., Shiratori T., Shimizu T., Miyazaki S., Okazumi S., Nabeya Y., Shuto K., Hayashi H., Tanizawa T., Nakatani Y., Nakasa H., Kitada M., Ochiai T., Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma Cancer Science 2006 97 6 554 561 (Pubitemid 43811599)
57. Brown C. J., Lain S., Verma C. S., Fersht A. R., Lane D. P., Awakening guardian angels: drugging the P53 pathway Nature Reviews Cancer 2009 9 12 862 873
58. Guo J., Xin H., Chinese gene therapy. Splicing out the West? Science 2006 314 5803 1232 1235 (Pubitemid 44846373)
59. Rosenberg S. A., A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity 1999 10 3 281 287 (Pubitemid 29165283)
60. DeLeo A. B., P53-based immunotherapy of cancer Critical Reviews in Immunology 1998 18 1-2 29 35 (Pubitemid 27528179)
61. Sangrajrang S., Sornprom A., Chernrungroj G., Soussi T., Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking Lung Cancer 2003 39 3 297 301 (Pubitemid 36284730)
62. Vojtesek B., Kovarik J., Dolezalova H., Nenutil R., Havlis P., Brentani R. R., Lane D. P., Absence of p53 autoantibodies in a significant proportion of breast cancer patients British Journal of Cancer 1995 71 6 1253 1256
63. Speetjens F. M., Kuppen P. J. K., Welters M. J. P., Essahsah F., Van Den Brink A. M. E. G. V., Lantrua M. G. K., Valentijn A. R. P. M., Oostendorp J., Fathers L. M., Nijman H. W., Drijfhout J. W., Van De Velde C. J. H., Melief C. J. M., Van Der Burg S. H., Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer Clinical Cancer Research 2009 15 3 1086 1095
64. Cheok C. F., Verma C. S., Baselga J., Lane D. P., Translating p53 into the clinic Nature Reviews Clinical Oncology 2011 8 1 25 37
65. Chiappori A. A., Soliman H., Janssen W. E., Antonia S. J., Gabrilovich D. I., INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect Expert Opinion on Biological Therapy 2010 10 6 983 991
66. Green D. R., Kroemer G., Cytoplasmic functions of the tumour suppressor p53 Nature 2009 458 7242 1127 1130
67. Caelles C., Helmberg A., Karin M., P53-dependent apoptosis in the absence of transcriptional activation of p53-target genes Nature 1994 370 6486 220 223 (Pubitemid 24236778)
68. Chipuk J. E., Maurer U., Green D. R., Schuler M., Pharmacologic activation of p53 elicits bax -dependent apoptosis in the absence of transcription Cancer Cell 2003 4 5 371 381 (Pubitemid 37491098)
69. Meletis K., Wirta V., Hede S. M., Nistér M., Lundeberg J., Frisén J., P53 suppresses the self-renewal of adult neural stem cells Development 2006 133 2 363 369 (Pubitemid 43210724)
70. Liu Y., Elf S. E., Miyata Y., Sashida G., Liu Y., Huang G., Di Giandomenico S., Lee J. M., Deblasio A., Menendez S., Antipin J., Reva B., Koff A., Nimer S. D., P53 regulates hematopoietic stem cell quiescence Cell Stem Cell 2009 4 1 37 48
71. Zhao Z., Zuber J., Diaz-Flores E., P53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal Genes Development 2010 24 13 1389 1402
72. Cicalese A., Bonizzi G., Pasi C. E., Faretta M., Ronzoni S., Giulini B., Brisken C., Minucci S., Di Fiore P. P., Pelicci P. G., The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells Cell 2009 138 6 1083 1095